• Market Capitalisation market-capitalisation-info $233 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-19 Mln

Fate Therapeutics Inc. (FATE) Share Price

$2.40

As on 06-Dec-2023 16:00 EST

up-down-arrow $0.031.27%

  • Prev Close info

    $2.37

  • Day's Openinfo

    $2.39

  • Today's Highinfo

    $2.50

  • Today's Lowinfo

    $2.29

  • Today's Volumeinfo

    1,261,509

  • 52 Week rangeinfo

    $1.63 - 19.57

Please wait...

Fate Therapeutics Inc. (FATE) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Fate Therapeutics (FATE)
-76.21 0.42 -11.44 -88.24 -65.95 -32.38 -8.97
S&P BSE Sensex*
14.32 7.08 5.58 11.06 15.55 14.52 12.72
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 06-Dec-2023  |  *As on 07-Dec-2023  |  #As on 26-Oct-2023
2022
2021
2020
2019
2018
2017
2016
Fate Therapeutics (FATE)
-82.76 -35.65 364.64 52.53 109.14 143.43 -25.52
S&P Small-Cap 600
-17.42 25.27 9.57 20.86 -9.70 11.73 24.74
S&P BSE Sensex
4.44 21.99 15.75 14.38 5.87 27.91 1.95

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Fate Therapeutics Inc. (FATE) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Fate Therapeutics Inc. (FATE)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Fate Therapeutics Inc. (FATE)

        Founder, CEO, Pres & Director

        Mr. J. Scott Wolchko

        Chief Financial Officer

        Mr. Edward J. Dulac III

        Headquarters

        San Diego, CA

        FAQs for Fate Therapeutics Inc. (FATE)

        The total asset value of Fate Therapeutics Inc. (FATE) stood at $ 585 Mln as on 30-Sep-23

        The share price of Fate Therapeutics Inc. (FATE) is $2.40 (NASDAQ) as of 06-Dec-2023 16:00 EST. Fate Therapeutics Inc. (FATE) has given a return of -65.95% in the last 3 years.

        Fate Therapeutics Inc. (FATE) has a market capitalisation of $ 233 Mln as on 24-Nov-2023. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Fate Therapeutics Inc. (FATE) is 2.88 times as on 24-Nov-2023, a 0.13% premium to its peers’ median range of 2.54 times.

        Since, TTM earnings of Fate Therapeutics Inc. (FATE) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Fate Therapeutics Inc. (FATE) and enter the required number of quantities and click on buy to purchase the shares of Fate Therapeutics Inc. (FATE).

        Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

        The CEO & director of Mr. J. Scott Wolchko. is Fate Therapeutics Inc. (FATE), and CFO & Sr. VP is Mr. Edward J. Dulac III.

        The promoters of Fate Therapeutics Inc. (FATE) have pledged 0% of the total equity as on Jun-23.

        Fate Therapeutics Inc. (FATE) Ratios
        Return on equity(%)
        -35.31
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Fate Therapeutics Inc. (FATE) was $-19 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $232.70 Mln
        • Revenue (TTM)revenue-information $106.21 Mln
        • Earnings (TTM) earning-information $-18.88 Mln
        • Cash date-information $349.73 Mln
        • Total Debt info $104.95 Mln
        • Insider's Holding 1.45%
        • Liquidity liquidity High
        • 52 Week range week-range $1.63 - 19.57
        • Shares outstanding share-outstanding 98,602,000
        • 10 Years Aggregate:

          CFO: $-695.05 Mln

          EBITDA: $-954.22 Mln

          Net Profit: $-949.15 Mln

        About The Company

        • IPO Date 01-Oct-2013
        • Founder, CEO, Pres & Director Mr. J. Scott Wolchko
        • Chief Financial Officer Mr. Edward J. Dulac III
        • Listing key-listing NASDAQ: FATE
        • Country United States
        • Headquarters headquarters San Diego, CA
        • Website website https://www.fatetherapeutics.com
        • Business

          Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576...  to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon